A Novel NIR-Controlled NO Release Of Sodium Nitroprusside-Doped Prussian Blue Nanoparticle For Synergistic Tumor Treatment

Nitric oxide(NO)has shown exciting effects in the treatment of tumor,however,controlling the release of NO to specific targets is still a crucial challenge for its antitumor therapy.Utilizing the phenomenon that sodium nitroprusside(SNP)and potassium ferricyanide have similar chemical structures,a near infrared laser(NIR)-controlled NO release nanoplatform has been fabricated by allowing SNP to participate in the formation of mesoporous Prussian blue nanoparticles(m-PB).The resultant SNP-doped m-PB(m-PB-NO)exhibited a good NIR-controlled NO release behavior and the amount of NO released could be controlled by adjusting the laser intensity and the irradiation time.Since m-PB-NO still has strong absorption in the NIR region,it exhibited an excellent photothermal effect both in vitro and in vivo.After carrying antitumor drug,docetaxel-loaded m-PB-NO(DTX@m-PB-NO)could simultaneously achieve NIR-controlled NO release,good photothermotherapy and chemotherapy.And the combination therapy of DTX@m-PB-NO showed a significant synergistic effect compared to either therapy alone,and could significantly improve the therapeutic effect.Furthermore,combination therapy significantly inhibited lung metastasis of 4T1 breast cancer cells in tumor-bearing mice by ablating primary tumors.